Anthony Sanfiz

Statistics

Publications

Citations

502

H-Index

Active since

2001

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Rockefeller University

Anthony Sanfiz is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, cell signaling, and potency optimization.

Publications per year

2001–2019

Publications

Regulation of PTEN binding to MAGI-2 by two putative phosphorylation sites at threonine 382 and 383.

Tatyana Tolkacheva, M Boddapati, Anthony Sanfiz et al. · PubMed · 2001 · 149 citations

Life Sciences, Cell Biology, Molecular Biology +14

Tyrosine sulfation of CCR5 N-terminal peptide by tyrosylprotein sulfotransferases 1 and 2 follows a discrete pattern and temporal sequence

Christoph Seibert, Martine Cadène, Anthony Sanfiz et al. · Proceedings of the National Academy of Sciences · 2002 · 108 citations · Full text

Life Sciences, Biochemistry, Immunology +17

Discovery of Vibegron: A Potent and Selective β<sub>3</sub>Adrenergic Receptor Agonist for the Treatment of Overactive Bladder

Scott D. Edmondson, Cheng Zhu, Nam Fung Kar et al. · Journal of Medicinal Chemistry · 2015 · 102 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder

Jerry Di Salvo, Hiroshi Nagabukuro, L. Alexandra Wickham et al. · Journal of Pharmacology and Experimental Therapeutics · 2016 · 59 citations

Medicine, Pharmacology, Pharmacotherapy +17

Development and validation of an in vitro 3D model of NASH with severe fibrotic phenotype.

Sumanta Mukherjee, Leonid Zhelnin, Anthony Sanfiz et al. · PubMed · 2019 · 38 citations

Veterinary Medicine, Cell Biology, Translational Sciences +17

1–5 of 8